Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1051/medsci/20173306008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human adenovirus type 7 subunit vaccine induces dendritic cell maturation through the TLR4/NF-κB pathway is highly immunogenic.
Front Cell Infect Microbiol
May 2023
Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, China.
Article Synopsis
- Human adenovirus type 7 (HAdv-7) is a major cause of respiratory infections in children, and there are currently no available treatments or vaccines, making the development of a safe vaccine essential.
- The study created a recombinant subunit vaccine using a baculovirus-insect cell system to express the HAdv-7 hexon protein, aiming to elicit strong immune responses.
- Results indicated that this vaccine effectively enhanced immune responses by improving antigen uptake and activating T cells, showing potential as a future vaccine against HAdv-7.
Human adenovirus type 7 virus-like particle vaccine induces Dendritic cell maturation through the TLR4/NF-κB pathway and is highly immunogenic.
Antiviral Res
April 2023
Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun, 130117, PR China; Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130122, PR China. Electronic address:
Human adenovirus type 7 (HAdv-7) infection is the main cause of upper respiratory tract infection, bronchitis and pneumonia in children. At present, there are no anti-adenovirus drugs or preventive vaccines in the market. Therefore, it is necessary to develop a safe and effective anti-adenovirus type 7 vaccine.
View Article and Find Full Text PDFImpact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
J Infect Dis
September 2022
Janssen Vaccines and Prevention, Leiden, the Netherlands.
This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody levels in 380 participants in Brazil, South Africa, and the United States.
View Article and Find Full Text PDFSafety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial.
Vaccines (Basel)
March 2021
Altimmune, Inc., Gaithersburg, MD 20878, USA.
Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune responses, weak cellular immune responses, and insufficiently durable immune responses. The safety and immunogenicity of NasoVAX, a monovalent intranasal influenza vaccine based on a replication-deficient adenovirus type 5 platform, were evaluated in a placebo-controlled single ascending-dose study.
View Article and Find Full Text PDFHumoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells.
PLoS Pathog
August 2018
Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Following repeated encounters with adenoviruses most of us develop robust humoral and cellular immune responses that are thought to act together to combat ongoing and subsequent infections. Yet in spite of robust immune responses, adenoviruses establish subclinical persistent infections that can last for decades. While adenovirus persistence pose minimal risk in B-cell compromised individuals, if T-cell immunity is severely compromised reactivation of latent adenoviruses can be life threatening.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!